EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Effects of a Dulaglutide plus Calorie-Restricted Diet versus a Calorie-Restricted Diet on Visceral Fat and Metabolic Profiles in Women with Polycystic Ovary Syndrome: A Randomized Controlled Trial

Yuqin Zhang, Zhihua Qu, Ting Lu, Xiaowen Shao, Meili Cai, Diliqingna Dilimulati, Xinxin Gao, Weiqing Mao, Fan Hu, Lili Su, Qiong Liao, Ting Han und 2 weitere

Nutrients · 20.01.2023 · 15 (3) · 556

DOI: 10.3390/nu15030556 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Nutrients, online erschienen am 20.01.2023. Verfasst von Yuqin Zhang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai 200072, China. Hauptthemen laut MEDLINE: Obesity, Overweight, Polycystic Ovary Syndrome, Caloric Restriction. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Nature Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The effects of dulaglutide and a calorie-restricted diet (CRD) on visceral adipose tissue (VAT) and metabolic profiles in polycystic ovary syndrome (PCOS) have not been extensively investigated. In this study, we investigated whether dulaglutide combined with CRD could further reduce VAT and promote clinical benefits as compared with a CRD regimen alone in overweight or obese PCOS-affected women. Between May 2021 and May 2022, this single-center, randomized, controlled, open-label clinical trial was conducted. Overall, 243 participants with PCOS were screened, of which 68 overweight or obese individuals were randomly randomized to undergo dulaglutide combined with CRD treatment (n = 35) or CRD treatment alone (n = 33). The duration of intervention was set as the time taken to achieve a 7% weight loss goal from baseline body weight, which was restricted to 6 months. The primary endpoint was the difference in the change in VAT area reduction between the groups. The secondary endpoints contained changes in menstrual frequency, metabolic profiles, hormonal parameters, liver fat, and body composition. As compared with the CRD group, the dulaglutide + CRD group had a considerably shorter median time to achieve 7% weight loss. There was no significant between-group difference in area change of VAT reduction (−0.97 cm2, 95% confidence interval from −14.36 to 12.42, p = 0.884). As compared with CRD alone, dulaglutide + CRD had significant advantages in reducing glycated hemoglobin A1c and postprandial plasma glucose levels. The results of the analyses showed different changes in menstruation frequency, additional metabolic profiles, hormonal markers, liver fat, and body composition between the two groups did not differ significantly. Nausea, vomiting, constipation, and loss of appetite were the main adverse events of dulaglutide. These results emphasize the value of dietary intervention as the first line of treatment for PCOS-affected women, while glucagon-like peptide 1 receptor agonist therapy provides an efficient and typically well tolerated adjuvant therapy to aid in reaching weight targets based on dietary therapy in the population of overweight/obese PCOS-affected women.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ObesityOverweightPolycystic Ovary SyndromeCaloric RestrictionFemaleHumansIntra-Abdominal FatWeight LossGlucagon-Like PeptidesImmunoglobulin Fc FragmentsRecombinant Fusion Proteins

Stichwörter der Autor:innen

calorie-restricted dietdulaglutideglucagon-like peptide 1 receptor agonistpolycystic ovary syndromevisceral adipose tissue

Substanzen

dulaglutideGlucagon-Like PeptidesImmunoglobulin Fc FragmentsRecombinant Fusion Proteins

Autor:innen und Institutionen

  • Department of Endocrinology and Metabolism, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai 200072, China.
  • Department of Nutrition, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai 200072, China.
  • Department of Obstetrics and Gynecology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai 200072, China.
  • Department of Nuclear Medicine, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai 200072, China.

ORCID-Profile: Manna Zhang, Shen Qu

Förderung

  • National Nature Science Foundation

Zitieren

APA

Zhang, Y., Qu, Z., Lu, T., Shao, X., Cai, M., Dilimulati, D., Gao, X., Mao, W., Hu, F., Su, L., Liao, Q., Han, T., Zhang, M., & Qu, S. (2023). Effects of a Dulaglutide plus Calorie-Restricted Diet versus a Calorie-Restricted Diet on Visceral Fat and Metabolic Profiles in Women with Polycystic Ovary Syndrome: A Randomized Controlled Trial. Nutrients, 15(3), 556. https://doi.org/10.3390/nu15030556

Vancouver

Zhang Y, Qu Z, Lu T, Shao X, Cai M, Dilimulati D, et al. Effects of a Dulaglutide plus Calorie-Restricted Diet versus a Calorie-Restricted Diet on Visceral Fat and Metabolic Profiles in Women with Polycystic Ovary Syndrome: A Randomized Controlled Trial. Nutrients. 2023;15(3):556. doi:10.3390/nu15030556

BibTeX
@article{Zhang2023,
  author = {Zhang, Yuqin and Qu, Zhihua and Lu, Ting and Shao, Xiaowen and Cai, Meili and Dilimulati, Diliqingna and Gao, Xinxin and Mao, Weiqing and Hu, Fan and Su, Lili and Liao, Qiong and Han, Ting and Zhang, Manna and Qu, Shen},
  title = {Effects of a Dulaglutide plus Calorie-Restricted Diet versus a Calorie-Restricted Diet on Visceral Fat and Metabolic Profiles in Women with Polycystic Ovary Syndrome: A Randomized Controlled Trial},
  journal = {Nutrients},
  year = {2023},
  volume = {15},
  number = {3},
  pages = {556},
  doi = {10.3390/nu15030556}
}
Kostenlos starten →